Description
This fixed-dose combination of Levodopa and Benserazide is a gold standard model compound for experimental studies of Parkinson’s disease, particularly in understanding dopamine biosynthesis, metabolism, and central nervous system neurotransmission.
Benserazide acts as a DOPA decarboxylase inhibitor, enhancing Levodopa’s bioavailability in the brain while reducing peripheral side effects—making this pairing useful for controlled experimental models in pharmacological and neuroscience research.
Levodopa and Benserazide Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Levodopa and Benserazide Tablets |
| Brand Name | Weiliding |
| Active Ingredients | Levodopa (200?mg) + Benserazide Hydrochloride (50?mg) |
| CAS Number | Levodopa: 59-92-7; Benserazide: 14919-77-8 |
| Molecular Formula | Levodopa: C9H11NO4; Benserazide: C10H15N3O5 |
| Molecular Weight | Levodopa: 197.19 g/mol; Benserazide: 257.24 g/mol |
| Dosage Form | Oral tablet |
| Strength | 0.25g (200?mg/50?mg) per tablet |
| Pack Size | 40 tablets per box |
| Approval Number | H20243207 (NMPA, China) |
| Drug Code | 86904647001508 |
| Manufacturer | Zhejiang Huahai Pharmaceutical Co., Ltd. |
| Barcode | 6958439004691 |
| Storage Conditions | Store below 25°C; protect from moisture and light |
| Intended Use | Laboratory research only |
Levodopa and Benserazide Mechanism of Action
Levodopa serves as a direct precursor to dopamine. It crosses the blood-brain barrier and is converted to dopamine in the central nervous system, restoring dopaminergic function.
Benserazide is a peripheral decarboxylase inhibitor, preventing Levodopa from premature conversion into dopamine outside the brain—enhancing central activity while reducing side effects.
This synergistic action is frequently studied in Parkinsonian rodent models, motor learning simulations, and dopamine pathway mapping.
Research Applications
Parkinson’s Disease Models
Evaluate Levodopa’s effects on motor control, bradykinesia, tremors, and muscle rigidity in animal models.Dopamine Pathway Studies
Analyze synaptic dopamine release, receptor activation, and neuroadaptive responses to long-term administration.Drug Interaction Studies
Test interactions between dopamine agonists, anticholinergics, and MAO-B inhibitors in polypharmacy research settings.Neurotoxicity and Side Effect Profiling
Assess long-term neurochemical and behavioral changes, including potential dyskinesias or tolerance.
Safety & Handling
Handling Instructions: Use gloves and PPE. Avoid skin or mucosal exposure.
Storage: Keep sealed in original packaging. Store below 25?°C.
Shelf Life: 24–36 months under standard research storage conditions.
Toxicological Caution: High-dose exposure may alter neurotransmitter balance in test subjects—monitor carefully during extended studies.
Research Use Disclaimer
This product is designated solely for scientific laboratory research purposes. It is not to be used in humans, animals, or for diagnostic or therapeutic applications. Users must follow all institutional and legal compliance for handling and storage.


Reviews
There are no reviews yet.